OXYMETAZOLINE HYDROCHLORIDE

US Approved OTC

First approved in 1964

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H24N2O.ClH
Molecular Weight	296.836
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of OXYMETAZOLINE HYDROCHLORIDE

Structure Search

SMILES

Cl.CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C

InChI

InChIKey=BEEDODBODQVSIM-UHFFFAOYSA-N

InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H24N2O
Molecular Weight	260.3746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00935
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/monograph/oxymetazoline-hydrochloride.html

Oxymetazoline is an adrenergic alpha-agonist, direct acting sympathomimetic, used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis. Oxymetazoline is self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. Oxymetazoline is available over-the-counter as a topical decongestant in the form of oxymetazoline hydrochloride in nasal sprays such as Afrin, Operil, Dristan, Dimetapp, oxyspray, Facimin, Nasivin, Nostrilla, Sudafed OM, Vicks Sinex, Zicam, SinuFrin, and Mucinex Full Force. Due to its vasoconstricting properties, oxymetazoline is also used to treat nose bleeds and eye redness.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/20030735 \| https://www.ncbi.nlm.nih.gov/pubmed/11844675	Agonist 2637	4.96 null [pEC50]
Alpha-2a adrenergic receptor 60 Target ID: CHEMBL1867 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/24365159 \| https://www.ncbi.nlm.nih.gov/pubmed/1974694	Partial Agonist 283	0.29 nM [Ki]
Serotonin 1a (5-HT1a) receptor 171 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2637	7.73 null [pEC50]
Serotonin 1d (5-HT1d) receptor 52 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2637	7.35 null [pEC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nasal congestion 26 Sources: https://www.drugs.com/ppa/oxymetazoline-nasal.html	Palliative		Approved 8307	Oxymetazoline Hydrochloride Approved Use Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure. Launch Date 6.0721922E11
Eye irritations 2 Sources: https://www.drugs.com/cdi/oxymetazoline-drops.html	Primary		Approved 8307	OCUCLEAR Approved Use Relief of redness of eye due to minor eye irritations Launch Date 5.17795185E11

C_max

Value	Dose	Co-administered	Analyte	Population
60.5 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.78 ng/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
895 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.24 ng × h/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.23 h DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	Other AEs: Hypertensive crisis... Other AEs: Hypertensive crisis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	Disc. AE: Application site dermatitis, Application site erythema... AEs leading to discontinuation/dose reduction: Application site dermatitis (1.4%) Application site erythema (0.5%) Application site pain (0.5%) Application site dryness (0.2%) Hypoesthesia (0.2%) Paresthesia (0.2%) Rash (0.2%) Urticaria (0.2%) Photosensitivity reaction (0.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
1.5 % 2 times / day multiple, topical Highest studied dose Dose: 1.5 %, 2 times / day Route: topical Route: multiple Dose: 1.5 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	unhealthy, adult Health Status: unhealthy Condition: Erythema Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	Sources: https://pubmed.ncbi.nlm.nih.gov/29462230

AEs

AE	Significance	Dose	Population
Hypertensive crisis	1 patient	0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
Application site dryness	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Hypoesthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Paresthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Photosensitivity reaction	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Rash	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Urticaria	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site erythema	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site pain	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site dermatitis	1.4% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 753 substrate 1670	inhibitor 1695 substrate 985	inhibitor 1789 substrate 1168	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2B6 770 CYP2C8 869 CYP2C19 1410 CYP3A4/5 261	CYP2C19 955 CYP1A2 1013 CYP2B6 648 CYP2C8 670 CYP2C18 138 CYP2E1 633 UGT1A9 378 UGT1A1 417 UGT1A3 421 UGT1A4 345 UGT1A6 306 UGT1A8 282 UGT1A10 289 UGT2B4 248 UGT2B7 387 UGT2B15 202 UGT2B17 212	CYP1A2 671 CYP2B6 521

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1620	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 946	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 946	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4 1857	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4/5 314	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1013	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2B6 648	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C18 138	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C8 670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C9 985	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2D6 1168	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2E1 633	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP3A4 1670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
UGT1A1 417	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A10 289	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A3 421	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A4 345	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A6 306	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A8 282	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B15 202	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B17 212	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B4 248	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B7 387	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A9 378	substrate 3264 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	yes
CYP2C19 955	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0	yes	no (co-administration study) Comment: concomitant oral moderate CYP2C19 inhibitors (e.g., esomeprazole, fluoxetine, and omeprazole): the results did not indicate an increase in oxymetazoline exposure associated with coadministration of oral moderate CYP2C19 inhibitors Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208552Orig1s000PharmR.pdf#page=19 Page: 19.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7862	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7862
ChemicalBook	CB0371500	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0371500
ZINC	ZINC000000057435	http://zinc15.docking.org/substances/ZINC000000057435
eMolecules	902254	https://www.emolecules.com/cgi-bin/more?vid=902254

PubMed

Title	Date	PubMed
Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells.	1999 Jun	10433504
Evidence for a non-adrenoceptor, imidazoline-mediated contractile response to oxymetazoline in the porcine isolated rectal artery.	2001 Apr	11264227
Presynaptic alpha2-adrenoceptor-mediated modulation of adenosine 5' triphosphate and noradrenaline corelease: differences in canine mesenteric artery and vein.	2001 Feb	11422578
Reduced baroreceptor sensitivity during hypotension in ANP-knockout mice.	2001 Mar	11294595
Effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain.	2001 Mar	11245411
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.	2001 May	11383713
Inhibition of synovial plasma extravasation by preemptive administration of an antiinflammatory irrigation solution in the rat knee.	2001 May	11323366
Renal actions of the alpha2-adrenoceptor agonist, xylazine, in the anaesthetised rat.	2001 Oct	16032189
Increased nasal mucosal swelling in subjects with asthma.	2002 Jan	12002739
Intracellular sodium modulates the state of protein kinase C phosphorylation of rat proximal tubule Na+,K+-ATPase.	2002 Jun	12028137
Effects of oxymetazoline on the ventilation of paranasal sinuses in healthy subjects.	2002 Mar-Apr	12030359
Search of antimicrobial activity of selected non-antibiotic drugs.	2002 Nov-Dec	12669766
alpha 2B-Adrenoceptor levels govern agonist and inverse agonist responses in PC12 cells.	2003 Aug 15	12890472
Effects of acute, repeated and chronic variable stress on in vivo tyrosine hydroxylase activity and on alpha(2)-adrenoceptor sensitivity in the rat brain.	2003 Dec	14660060
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.	2003 Jul	12791938
[Acute exposure to imidazoline derivatives in children].	2003 Nov-Dec	14685449
Synthesis and identification of two potential oxidation degradants of oxymetazoline.	2004	15282792
Chronic rhinosinusitis: management for optimal outcomes.	2004	15182211
Antimuscarinic action of oxymetazoline on human intraocular muscles.	2004 Aug	15321027
Behavioral effects of serotonin and serotonin agonists in two crayfish species, Procambarus clarkii and Orconectes rusticus.	2004 Dec	15596395
The Janus faces of adrenoceptors: factors controlling the coupling of adrenoceptors to multiple signal transduction pathways.	2004 Nov	15566401
Differential distribution of functional alph}1-adrenergic receptor subtypes along the rat tail artery.	2005 Aug	15872040
Is oxymetazoline really safe for middle ear use.	2005 Jul	15995530

Patents

Sample Use Guides

In Vivo Use Guide

Pediatric Patients Nasal Congestion Intranasal For self-medication in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed. Adults Nasal Congestion Intranasal For self-medication: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Route of Administration: Nasal

In Vitro Use Guide

Oxymetazoline had a concentration-dependent inhibitory effect on cultured human nasal CBF from 0.25 to 2.00 g/L.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 15:57:54 UTC 2022` Edited by `admin` on `Fri Dec 16 15:57:54 UTC 2022`
Record UNII	K89MJ0S5VY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYMETAZOLINE HYDROCHLORIDE

Official Name

English

OXYMETAZOLINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [MART.]

Common Name

English

KOVANAZE COMPONENT OXYMETAZOLINE HYDROCHLORIDE

Brand Name

English

NSC-757254

Code

English

UPNEEQ

Brand Name

English

AGN-199201

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [JAN]

Common Name

English

VISINE L.R.

Brand Name

English

SCH-9384

Code

English

Oxymetazoline hydrochloride [WHO-DD]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [USAN]

Common Name

English

PHENOL, 3-((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)-6-(1,1-DIMETHYLETHYL)-2,4-DIMETHYL-, MONOHYDROCHLORIDE

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [VANDF]

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE [MI]

Common Name

English

6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol monohydrochloride

Systematic Name

English

OCUCLEAR

Brand Name

English

OXYMETAZOLINE HCL

Common Name

English

OXYMETAZOLINE HYDROCHLORIDE COMPONENT OF KOVANAZE

Brand Name

English

SCH 9384

Code

English

OXYMETAZOLINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

RHOFADE

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29709